The DEXTER Robotic Surgery System is designed to be easy to move and use. Source: Distalmotion
Robot-assisted surgery is coming to more operating rooms. Distalmotion SA today said it has successfully closed its Series G financing round with $150 million. The medical technology company said it plans to use the funding to accelerate U.S. commercial of its DEXTER soft-tissue surgical robot, as well as to support ongoing clinical and product-development initiatives.
Distalmotion added that it is focusing on the U.S. ambulatory surgery center (ASC) market, which is one of the fastest-growing segments in surgical care because of the shift toward efficient outpatient surgery.
“This funding marks another important milestone on our journey,” stated Greg Roche, CEO of Distalmotion. “The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations.”
“As we enter our next phase of U.S. market acceleration, ASCs represent a tremendous opportunity for DEXTER,” he said. “The ongoing support from our investors reaffirms our roadmap, our mission, and the value DEXTER brings to minimally invasive surgery.”
Spun out of the Robotics Lab at the Swiss Federal Institute of Technology in Lausanne (EPFL) in 2012, Distalmotion said it is working to increase the number of patients who can benefit from best-in-class minimally invasive care. The Epalinges, Switzerland-based company has a U.S. office in Cleveland.
DEXTER keeps surgeons near patients
DEXTER is designed to bring wristed surgical robotics to operating rooms (ORs) of any size without modifications, according to Distalmotion. The company said the mobile system can be easily moved between rooms, quickly set up, and seamlessly integrated into existing procedures for optimal efficiency.
The system comes with a suite of fully wristed, single-use robotic instruments that enhance dexterity and precision, Distalmotion claimed.
DEXTER’s sterile console supports flexible surgical workflows by positioning the surgeon close to the patient for quick bedside access, noted the company. It also allows for easy transitions between laparoscopic and robotic techniques and enhanced communication with OR teams.
In addition, DEXTER’s open architecture enables compatibility with existing and future OR technologies, including visualization systems and advanced devices, for cost-effective supply chain operations, asserted Distalmotion.
DEXTER is commercially available in the U.S. and Europe. In the U.S., the Distalmotion Dexter L6 System is intended for use in laparoscopic inguinal hernia repair, cholecystectomy, and total benign hysterectomy including salpingo-oophorectomy. The system is indicated for adult use, defined as 22 years old and older.
In Europe, the Dexter L6 System is intended to assist in the accurate control of robotic instruments during urologic laparoscopic surgical procedures, general laparoscopic surgical procedures, and gynecologic laparoscopic surgical procedures. The system is indicated for adult use, said the company.
DEXTER is intended to be used on soft-tissue procedures in any OR. Source: Distalmotion
Distalmotion announces board chair
Distalmotion also named Chas McKhann as executive chairman of its board of directors. With more than 25 years in the MedTech and life sciences industries, McKhann has experience in scaling medical device companies, commercial acceleration, and guiding organizations through strategic growth.
He previously served as CEO of Apollo Endosurgery and then Silk Road Medical, two publicly traded medical device companies, where he drove sales growth that ultimately resulted in successful exits. Distalmotion said its appointment of McKhann demonstrates its commitment to establishing DEXTER as a leading system in ASCs.
“Distalmotion has reimagined how robotic surgery can be adopted across care settings because DEXTER delivers all the benefits of robotic surgery – dexterity, precision, and ergonomics – while also offering flexibility, efficiency, and value,” McKhann said. “With the recent FDA clearance in gynecology and release of DEXTER product enhancements, the company is poised to accelerate adoption in the U.S. and globally at this pivotal stage in its growth trajectory.”
Revival Healthcare Capital led Distalmotion’s Series G round, with participation from inside investors. DEXTER has already been integrated into clinical practices across Europe and the U.S., with almost 3,000 patients treated, noted Distalmotion.
Tell Us What You Think!